Prior to her roles in biopharma, Laurel had senior HR roles at Raytheon, Merck Millipore, and Bruker. Laurel Ostrom added: “During this period of growth and transformation, it is critical we attract ...

After hours: October 18 at 7:56 PM EDT Loading Chart for MRK ...

Dividend stocks offer long-term investors unique benefits.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

After hours: October 16 at 7:58 PM EDT ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Rumours that Merck was planning a $30 billion-plus takeover bid for Seagen have so far come to nothing, but it did complete a deal to buy VelosBio for $2.75 billion in late 2020 to add an ADC ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

In a report released on October 4, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $140.00. The company’s shares closed ...